Skip to main content
. Author manuscript; available in PMC: 2021 Jun 24.
Published in final edited form as: Leukemia. 2019 May 21;33(10):2540–2544. doi: 10.1038/s41375-019-0476-y

Figure 1: Timeline of events for all patients.

Figure 1:

CGVHD, chronic graft versus host disease; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CR, complete response; CY, cyclophosphamide; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; Gem, gemcitabine; GVHD, graft versus host disease; lb, ibrutinib; ICE, ifosfamide, carboplatin and etoposide; IS, immunosuppression therapy; L, lenalidomide; Liso, Lisocabtagene Maraleucel; M, methotrexate; Ox, oxaliplatin; PR, partial response; PD, progressive disease; R, rituximab; Th, Thiotepa; XRT, radiation therapy